Share-based Payment Arrangement, Expense of Rallybio Corp from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Rallybio Corp quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 30 Sep 2025.
  • Rallybio Corp Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,047,000, a 48% decline year-over-year.
  • Rallybio Corp Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $6,503,000, a 24% decline year-over-year.
  • Rallybio Corp annual Share-based Payment Arrangement, Expense for 2024 was $7,993,000, a 27% decline from 2023.
  • Rallybio Corp annual Share-based Payment Arrangement, Expense for 2023 was $10,920,000, a 15% increase from 2022.
  • Rallybio Corp annual Share-based Payment Arrangement, Expense for 2022 was $9,499,000, a 161% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Rallybio Corp Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $6,503,000 $1,047,000 -$980,000 -48% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $7,483,000 $1,614,000 -$301,000 -16% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $7,784,000 $1,879,000 -$209,000 -10% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $7,993,000 $1,963,000 -$586,000 -23% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $8,579,000 $2,027,000 -$607,000 -23% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $9,186,000 $1,915,000 -$777,000 -29% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $9,963,000 $2,088,000 -$957,000 -31% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $10,920,000 $2,549,000 +$255,000 +11% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $10,665,000 $2,634,000 +$130,000 +5.2% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $10,535,000 $2,692,000 +$45,000 +1.7% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $10,490,000 $3,045,000 +$991,000 +48% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $9,499,000 $2,294,000 +$765,000 +50% 01 Oct 2022 31 Dec 2022 10-K 12 Mar 2024 2023 FY
Q3 2022 $8,734,000 $2,504,000 +$1,449,000 +137% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $7,285,000 $2,647,000 +$2,108,000 +391% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $5,177,000 $2,054,000 +$1,532,000 +293% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $3,645,000 $1,529,000 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
Q3 2021 $1,055,000 +$780,000 +284% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $539,000 +$445,000 +473% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $522,000 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q3 2020 $275,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $94,000 01 Apr 2020 30 Jun 2020 10-Q 09 Sep 2021 2021 Q2

Rallybio Corp Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $7,993,000 -$2,927,000 -27% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $10,920,000 +$1,421,000 +15% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $9,499,000 +$5,854,000 +161% 01 Jan 2022 31 Dec 2022 10-K 12 Mar 2024 2023 FY
2021 $3,645,000 +$2,941,000 +418% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
2020 $704,000 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.